Article Text

other Versions

PDF
Research
Effect of azathioprine intolerance on outcomes of inflammatory bowel disease: a cross-sectional study
  1. Lennard Y W Lee,
  2. Anjum Syed Gardezi,
  3. Vidya Santharam,
  4. Jason Boyd,
  5. Sandro Lanzon-Miller
  1. Department of Gastroenterology, Milton Keynes NHS Foundation Trust, Standing Way, Milton Keynes, UK
  1. Correspondence to Dr Lennard Lee, Milton Keynes NHS Foundation Trust, Standing Way, Milton Keynes MK6 5LD, UK; lennardywlee{at}gmail.com

Abstract

Background Azathioprine is well established for the maintenance of remission in patients with inflammatory bowel disease (IBD). However, a significant proportion of patients are intolerant to azathioprine. It is not clear if intolerance of azathioprine is a marker of poor prognosis for patients who will have a more aggressive disease or be more likely to require surgery.

Objective To determine if intolerance to azathioprine is a marker of poor prognosis, indicating patients who have a more aggressive disease course, and to analyse the risk factors and causes of intolerance.

Methods A cross-sectional study using the Milton Keynes Hospital IBD database was performed to compare azathioprine-intolerant and azathioprine-tolerant patients.

Results Two hundred and thirty-nine patients met the inclusion criteria comprising 141 patients with Crohn's disease (CD) and 98 patients with ulcerative colitis (UC). Overall, 28.0% of patients were intolerant to azathioprine. Risk factors for intolerance were female sex and age 50–70 years. Common reasons for intolerance were nausea and vomiting (34.3%), deranged liver function tests (28.4%) and headaches (11.9%). In patients with UC, there was no statistical difference in the disease activity scores between those who were azathioprine intolerant versus tolerant. In patients with CD, azathioprine intolerance was associated with significantly worse disease activity; 25% fewer patients were in clinical remission and 20% more had moderate/severe disease. Rates of surgery were similar between the groups for both UC/CD.

Conclusions We conclude that azathioprine intolerance acts as a surrogate marker for patients with CD who in future have poorer symptom control. Azathioprine intolerance marks out a group of patients with CD in whom increased vigilance of symptom control and early escalation of treatment is required.

  • Azathioprine
  • Inflammatory Bowel Disease

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.